ClinConnect ClinConnect Logo
Search / Trial NCT03188874

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Launched by TECHNISCHE UNIVERSITÄT DRESDEN · Jun 13, 2017

Trial Information

Current as of August 21, 2025

Recruiting

Keywords

ClinConnect Summary

The Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) is a research study focused on understanding acute myeloid leukemia (AML) in adults who have just been diagnosed or are experiencing a relapse of the disease. This study is taking place at 51 locations across Germany and aims to gather important information about the disease, including how common it is, the factors that might influence a patient's outcome, and how long patients can expect to live without the disease coming back after treatment. By collecting this data, researchers hope to improve treatment strategies for AML in the future.

To participate in this study, adults aged 18 and older who have been diagnosed with AML, including a specific type called acute promyelocytic leukemia, can sign up. There are no upper age limits for this trial, and patients will be asked to give their written consent to participate. Once enrolled, participants can expect to have their treatment documented, and their progress tracked over time to better understand the disease and its outcomes. This research is crucial for helping doctors provide better care for those affected by AML.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
  • Age ≥ 18 years. There is no upper age limit.
  • Signed written informed consent
  • Exclusion Criteria:
  • there are no exclusion criteria

About Technische Universität Dresden

Technische Universität Dresden (TU Dresden) is a leading research institution in Germany, renowned for its commitment to advancing scientific knowledge and innovation across various disciplines, including medicine and healthcare. As a clinical trial sponsor, TU Dresden leverages its cutting-edge research facilities and interdisciplinary expertise to facilitate the development of novel therapeutic interventions and improve patient outcomes. The university fosters collaboration among academic, clinical, and industry partners, ensuring rigorous adherence to ethical standards and regulatory requirements in the conduct of clinical research. Through its dedication to excellence and research-driven initiatives, TU Dresden plays a pivotal role in translating scientific discoveries into practical applications that benefit society.

Locations

Erlangen, Bayern, Germany

Kiel, Schleswig Holstein, Germany

Leipzig, Sachsen, Germany

Berlin, , Germany

Aachen, Nordrhein Westfalen, Germany

Altenburg, , Germany

Leipzig, Sachsen, Germany

Jena, , Germany

Würzburg, Bayern, Germany

Augsburg, Bayern, Germany

Dresden, Sachsen, Germany

Halle (Saale), Sachsen Anhalt, Germany

Stuttgart, , Germany

Winnenden, , Germany

Düsseldorf, Nordrhein Westfalen, Germany

Frankfurt Am Main, Hessen, Germany

Münster, Nordrhein Westfalen, Germany

Halle (Saale), Sachsen Anhalt, Germany

Stendal, Sachsen Anhalt, Germany

Mannheim, , Germany

Chemnitz, Sachsen, Germany

Baden Baden, Baden Württemberg, Germany

Heidelberg, Baden Württemberg, Germany

Mannheim, Baden Württemberg, Germany

Schwäbisch Hall, Baden Württemberg, Germany

Sindelfingen, Baden Württemberg, Germany

Stuttgart, Baden Württemberg, Germany

Winnenden, Baden Württemberg, Germany

Bamberg, Bayern, Germany

Bayreuth, Bayern, Germany

Coburg, Bayern, Germany

Nürnberg, Bayern, Germany

Cottbus, Brandenburg, Germany

Frankfurt An Der Oder, Brandenburg, Germany

Fulda, Hessen, Germany

Marburg, Hessen, Germany

Wiesbaden, Hessen, Germany

Hildesheim, Niedersachsen, Germany

Rotenburg, Niedersachsen, Germany

Siegen, Nordhein Westfalen, Germany

Düren, Nordrhein Westfalen, Germany

Bielefeld, Nordrhein Westfalen, Germany

Bochum, Nordrhein Westfalen, Germany

Essen, Nordrhein Westfalen, Germany

Gütersloh, Nordrhein Westfalen, Germany

Hamm, Nordrhein Westfalen, Germany

Kaiserslautern, Rheinland Pfalz, Germany

Koblenz, Rheinland Pfalz, Germany

Riesa, Sachsen, Germany

Kiel, Schleswig Holstein, Germany

Altenburg, Thüringen, Germany

Jena, Thüringen, Germany

Bremen, , Germany

Baden Baden, , Germany

Neubrandenburg, Mecklenburg Vorpommern, Germany

Rostock, Mecklenburg Vorpommern, Germany

Duisburg, Nordrhein Westfalen, Germany

Siegen, Nordrhein Westfalen, Germany

Heidelberg, , Germany

Schwäbisch Hall, , Germany

Sindelfingen, , Germany

Patients applied

0 patients applied

Trial Officials

Christoph Röllig, Prof. Dr.

Study Director

Universitätsklinikum Carl Gustav Carus

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials